Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
Monday, November 13, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences presented late-breaking data on PBGENE-HBV at AASLD's The Liver Meeting 2023. The data showcases the preclinical efficacy and safety of PBGENE-HBV, which is designed to eliminate cccDNA and inactivate HBV DNA. Notably, the candidate achieved up to 99% viral engagement without off-target editing. The final clinical candidate is now ready for CTA and/or IND submission.
Price reaction · baseline $11.364 (2023-11-10 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-9.5%
day 1
-8.5%
day 3
+0.9%
Market Sentiment Analysis
POSITIVE FACTORS
Strong proof of concept efficacy demonstrated.
Up to 99% viral engagement achieved.
No detectable off-target editing at maximal dose.
Final clinical candidate ready for CTA and/or IND.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA – Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at maximal on-target editing dose – PBGENE-HBV final clinical candidate ready with CTA and/or IND
Frequently Asked Questions
What is PBGENE-HBV designed to do?
PBGENE-HBV is designed to eliminate cccDNA and inactivate HBV DNA.
What efficacy did PBGENE-HBV demonstrate?
PBGENE-HBV demonstrated up to 99% viral engagement in preclinical studies.
Was there any off-target editing observed?
No detectable off-target editing was observed at the maximal on-target editing dose.
What is the status of PBGENE-HBV?
PBGENE-HBV is now ready as a final clinical candidate for CTA and/or IND submission.